THE European Patent Office
has issued an Intention to Grant
for Progen Pharmaceuticals Ltd’s
patent application for ‘Sulfated
Oligosaccharide Derivatives’ No.
05706346.3, which protects the
company’s PG500 series of heparan
sulfate mimetic molecules and their
use in therapeutic areas largely
related to oncology, Progen said.
The lead compound in the series
was being tested in an open-label,
multi-centre Phase I study to
test the safety and tolerability by
intravenous infusion in patients
with advanced solid tumours.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jul 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.